When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1421 ET – Biotech’s year ahead looks uncertain, but it could ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Real estate giant Dar Global said it plans to expand in the U.S. and Greece after the Dubai-based developer recently unveiled projects in partnership with the Trump Organization, Reuters reported ...

A methane gas explosion caused a mine collapse in southwest Pakistan, trapping at least 12 miners. Rescue operations are ongoing in the Balochistan province with no rescues yet. The incident ...

As of 6 January at 10:47:00 am AEDT. Market open.